alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014303EN.01001901.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/19 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/19

---

Request for a preliminary ruling from the Tribunalul Timiș (Romania) lodged on 12 June 2014 — Silvia Ciup v Administrația Județeană a Finanțelor Publice (AJFP) Timiș — Direcția Generală Regională a Finanțelor Publice (DGRFP) Timișoara

(Case C-288/14)

2014/C 303/25

Language of the case: Romanian

Referring court

Referring court

Tribunalul Timiș

Parties to the main proceedings

Parties to the main proceedings

Applicant: Silvia Ciup

Applicant:

Defendant: Administrația Județeană a Finanțelor Publice (AJFP) Timiș — Direcția Generală Regională a Finanțelor Publice (DGRFP) Timișoara

Defendant:

Question referred

Question referred

Can the principles of equivalence and effectiveness of remedies for infringements of EU law, upheld by the case-law of the Court, and the right to property referred to in Article 17 of the Charter of Fundamental Rights of the European Union be interpreted as precluding provisions of national law that defer, on the basis of instalments payable over a period of five years, the reimbursement of taxes levied in breach of Community law and reimbursement of interest thereon, such reimbursements having been directed to be made by judgments that became enforceable by 31 December 2015?

---
#### § 520.1921 Prochlorperazine, isopropamide, and neomycin.

(a) *Specifications.* Each capsule contains either:

(1) Capsule No. 1: 3.33 milligrams of prochlorperazine (as the dimaleate), 1.67 milligrams of isopropamide (as the iodide), and 25 milligrams of neomycin base (as the sulfate); or

(2) Capsule No. 3: 10 milligrams of prochlorperazine (as the dimaleate), 5 milligrams of isopropamide (as the iodide), and 75 milligrams of neomycin base (as the sulfate).

(b) *Sponsor.* See No. 054771 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Conditions of use in dogs* —

(1) *Amount.* Administer capsules orally twice daily to dogs as follows:

| Animal weight (pounds) | Number of capsules per dose | |
| --- | --- | --- |
| Capsule No. 1 | Capsule No. 3 |
| 10 to 20 | 1 | |
| 20 to 30 | 2 | |
| Over 30 | 3 | 1 |
| Over 60 | | 2 |

(2) *Indications for use.* For the treatment infectious bacterial gastroenteritis associated with emotional stress.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[[49 FR 14103](https://www.federalregister.gov/citation/49-FR-14103), Apr. 10, 1984, as amended at [56 FR 50653](https://www.federalregister.gov/citation/56-FR-50653), Oct. 8, 1991; [60 FR 55659](https://www.federalregister.gov/citation/60-FR-55659), Nov. 2, 1995; [79 FR 28827](https://www.federalregister.gov/citation/79-FR-28827), May 20, 2014]
EXHIBIT 32
----------




                             CERTIFICATIONS OF
            CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                    PURSUANT TO 18 U.S.C. SECTION 1350,
                 AS ADOPTED PURSUANT TO SECTION 906 OF THE
                        SARBANES-OXLEY ACT OF 2002
            ---------------------------------------------------



      The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2007,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

      Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ALP Liquidating Trust.




                                         /s/   Gary Nickele
                                         ------------------------------
                                         Gary Nickele
                                         Chief Executive Officer




                                         /s/   Gailen J. Hull
                                         ------------------------------
                                         Gailen J. Hull
                                         Chief Financial Officer and
                                         Principal Accounting Officer
# L_2019292EN.01000201.xml

| 13.11.2019 | EN | Official Journal of the European Union | L 292/2 |
| --- | --- | --- | --- |

13.11.2019

EN

Official Journal of the European Union

L 292/2

---

COUNCIL DECISION (EU, Euratom) 2019/1898

of 8 November 2019

appointing a member, proposed by the Hellenic Republic,

of the European Economic and Social Committee

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 302 thereof,

Having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 106a thereof,

Having regard to the proposal of the Greek Government,

Having regard to the opinion of the European Commission,

Whereas:

| (1) | On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020. |
| --- | --- |

(1)

On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020.

| (2) | A member’s seat on the European Economic and Social Committee has become vacant following the end of the term of office of Mr Spyridon PAPASPYROS, |
| --- | --- |

(2)

A member’s seat on the European Economic and Social Committee has become vacant following the end of the term of office of Mr Spyridon PAPASPYROS,

HAS ADOPTED THIS DECISION:

Article 1

Mr Ioannis PAIDAS, President of the Executive Committee of ADEDY, is hereby appointed as a member of the European Economic and Social Committee for the remainder of the current term of office, which runs until 20 September 2020.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 8 November 2019.

For the Council

The President

L. ANDERSSON

---

(1)  Council Decision (EU, Euratom) 2015/1600 of 18 September 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 248, 24.9.2015, p. 53).

1

(2)  Council Decision (EU, Euratom) 2015/1790 of 1 October 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 260, 7.10.2015, p. 23).

2

---
Federal Aviation Administration 

Attention: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building-Suite 2Wl 000 

800 Independence Avenue, SW 

Washington, DC 20591 

May30, 2016 

RE: Case Name: 

Dear Administrator: 

Endless Mountains Air, Inc. 

Docket No. FAA-2013-0848 

Case No. 2012EA050008 

Seamans Airport 

65 Windsock Lane 

Factoryville, PA 18419 

Phone: 570.945.5125 

e-mail: billy@seamansairport.com 

website: www.seamansairport.com 

RECEIVED 

JUN 0 7 2016 

HEARING DOCKET 

Pleasebe advised that Endless Mountains Air, Inc. disagrees with the Initial Decision of U.S. Administrative 

Law Judge J .E. Sullivan and requests the opportunity to appeal the decision and subsequent civil penalty of 

$16,200. 

At the time of our hearing, current tax returns had not been filed by Endless Mountains Air, Inc and therefore 

could not be submitted to Judge Sullivan for review in our case. The reason for our delinquency with filing 

returns was due to the corporation having a large overdue balance with our accountants of which we were 

unable to satisfy prior to our March 10,2015 hearing. We were therefore unable to pay for tax return 

preparation since 2012 and were unfortunately unable to enter current returns as evidence at our hearing. 

Thankfully, we have satisfied our outstanding balance with our accountant and are only now begiuning to work 

toward completion of our overdue returns. 

I strongly believe that with review of recent federal tax returns, the Administrator will find that Endless 

Mountains Air is clearly unable to pay such a large civil penalty. 

Thank you for your consideration. If you have any questions, please feel free to contact me at any time. 

Sincerely, 

-) 

. Dobitsch, Jr., President 

ountains Air, Inc. 
SERVICE LIST- BY U.S. MAIL 

ORIGINAL & ONE COPY 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

Attention: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building- Suite 2Wl 0001 

Mr. Zachary M. Berman 

Complainant's Counsel 

Office of Regional Counsel, Eastern Region 

Federal Aviation Administration 

1 Aviation Plaza 

Jamaica, NY 11434 

TEL: 718-553-3258 

FAX: 718-995-5699 

Mr. William J. Dobitsch, Jr. 

Endless Mountains Air, Inc. 

Respondent 

Seamans Airport 

65 Windsock Lane 

Factoryville, PA 18419 

TEL: 570-945-5125 

FAX: 570-945-5953 

Judge J.E. Sullivan 

U.S. Administrative Law Judge 

Office of Hearings, M-20 

U.S. Department of Transportation 

1200 New Jersey Avenue, S.E. (E11-310) 

Washington, DC 20590 

TEL: 202-366-6941 

FAX: 202-366-7536 

ONE COPY
Editorial Note on Part 177
Editorial Note: Nomenclature changes to part 177 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 177.2430 Polyether resins, chlorinated. Chlorinated polyether resins may be safely used as articles or components of articles intended for repeated use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting, or holding food, in accordance with the following prescribed conditions: ( a ) The chlorinated polyether resins are produced by the catalytic polymerization of 3,3-bis(chloromethyl)-oxetane, and shall contain not more than 2 percent residual monomer.
( b ) In accordance with good manufacturing practice, finished articles containing the chlorinated polyether resins shall be thoroughly cleansed prior to their first use in contact with food.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

HADDRICK BYRD,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 290 EAL 2022

Petition for Allowance of Appeal

from the Order of the

Commonwealth Court

ORDER

PER CURIAM

AND NOW , this 26th day of April, 2023

, the Petition for Allowance of Appeal is

DENIED

.
#### The Southern Connecticut Gas Company *v.*Public Utilities Commission

King, C. J., Alcorn, House, Cotter and Ryan, Js.

Argued December 10

decided December 16, 1969

*627
      *John K. Jepson,*assistant attorney general, with whom were *Frank B. Odium,*assistant attorney general, and, on the brief, *Robert K. Killian,*attorney general, for the appellant (defendant).

*Raymond W. Beckwith,*with whom, on the brief, was *George N. Thim,*for the appellee (plaintiff).

Pee Curiam.

The Superior Court was without jurisdiction to enter the order appealed from and that order is vacated. General Statutes (Rev. to 1966) §§ 16-19, 16-22, 16-35, 16-37; *Wilson Point Property Owners Assn.*v. *Connecticut Light & Power Co.,*145 Conn. 243, 252, 140 A.2d 874; *Turner*v. *Connecticut Co.,*91 Conn. 692, 697, 101 A. 88.

In this opinion King, C. J., Alcorn, Cotter and Ryan, Js., concurred.

House, J.

(dissenting). Upon the limited record before us on this expedited appeal, I am unable to agree with the conclusion that it appears that the Superior Court lacked jurisdiction to entertain the appeal from the order of the Public Utilities Commission or to determine whether, if the court had jurisdiction, that jurisdiction was properly exercised.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Statement of Operations, Statement of Cash Flows and Notes thereto
incorporated in Part I, Item 1 of this Form 10-QSB and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          87,951
<SECURITIES>                                         0
<RECEIVABLES>                                  145,425
<ALLOWANCES>                                    40,415
<INVENTORY>                                          0
<CURRENT-ASSETS>                               229,724
<PP&E>                                         813,404
<DEPRECIATION>                                 246,336
<TOTAL-ASSETS>                                 819,112
<CURRENT-LIABILITIES>                          683,751
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    167,368
<COMMON>                                        11,731
<OTHER-SE>                                    (47,432)
<TOTAL-LIABILITY-AND-EQUITY>                   819,112
<SALES>                                        636,446
<TOTAL-REVENUES>                               636,446
<CGS>                                          111,721
<TOTAL-COSTS>                                  111,721
<OTHER-EXPENSES>                             1,275,631
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               9,758
<INCOME-PRETAX>                              (746,905)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (746,905)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (746,905)
<EPS-BASIC>                                     (0.06)
<EPS-DILUTED>                                   (0.06)



</TABLE>
V 

118TH CONGRESS 

1ST SESSION H. R. 740 

For the relief of Igor Klyuchenko. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2023 

Mr. DAVIS of Illinois introduced the following bill; which was referred to the 

Committee on the Judiciary 

A BILL 

For the relief of Igor Klyuchenko. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PERMANENT RESIDENT STATUS FOR IGOR 

4 KLYUCHENKO. 

5 (a) IN GENERAL.—Notwithstanding subsections (a) 

6 and (b) of section 201 of the Immigration and Nationality 

7 Act, Igor Klyuchenko shall be eligible for issuance of an 

8 immigrant visa or for adjustment of status to that of an 

9 alien lawfully admitted for permanent residence upon fil10 ing an application for issuance of an immigrant visa under 

11 section 204 of such Act or for adjustment of status to 

12 lawful permanent resident. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 740 IH

1 (b) ADJUSTMENT OF STATUS.—If Igor Klyuchenko 

2 enters the United States before the filing deadline speci3 fied in subsection (c), he shall be considered to have en4 tered and remained lawfully and shall, if otherwise eligible, 

5 be eligible for adjustment of status under section 245 of 

6 the Immigration and Nationality Act as of the date of the 

7 enactment of this Act. 

8 (c) DEADLINE FOR APPLICATION AND PAYMENT OF

9 FEES.—Subsections (a) and (b) shall apply only if the ap10 plication for issuance of an immigrant visa or the applica11 tion for adjustment of status is filed with appropriate fees 

12 within 2 years after the date of the enactment of this Act. 

13 (d) REDUCTION OF IMMIGRANT VISA NUMBER.— 

14 Upon the granting of an immigrant visa or permanent res15 idence to Igor Klyuchenko, the Secretary of State shall 

16 instruct the proper officer to reduce by 2, during the cur17 rent or next following fiscal year, the total number of im18 migrant visas that are made available to natives of the 

19 country of the alien’s birth under section 203(a) of the 

20 Immigration and Nationality Act or, if applicable, the 

21 total number of immigrant visas that are made available 

22 to natives of the country of the alien’s birth under section 

23 202(e) of such Act. 

24 (e) DENIAL OF PREFERENTIAL IMMIGRATION

25 TREATMENT FOR CERTAIN RELATIVES.—The natural 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•HR 740 IH

1 parents, brothers, and sisters of Igor Klyuchenko shall 

2 not, by virtue of such relationship, be accorded any right, 

3 privilege, or status under the Immigration and Nationality 

4 Act. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
§ 522.2460 Tildipirosin. ( a ) *Specifications.* Each milliliter of solution contains: ( 1 ) 180 milligrams (mg) tildipirosin.
( 2 ) [Reserved]
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.733 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Cattle* — ( i ) *Amount.* Administer 4 mg/kg of bodyweight one time by subcutaneous injection in the neck.
( ii ) *Indications for use.* For the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida,* and *Histophilus somni* in beef and non-lactating dairy cattle; and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica, P. multocida,* and *H. somni.*
( iii ) *Limitations.* Cattle intended for human consumption must not be slaughtered within 21 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[77 FR 39391, July 3, 2012]
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, August 14, 2018. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, August 14, 2018 The Court of Appeals hereby passes the following order A19I0001. TRISTAR AMERICA, LLC v. STAR HOME ENTERPRISES, LLC.
Upon consideration of the Application for Interlocutory Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 16C06468
# Third District Court of Appeal State of Florida Opinion filed March 2, 2022. Not final until disposition of timely filed motion for rehearing.

________________ No. 3D22-0089 Lower Tribunal No. F17-12432A

________________ Maurice Lindsey, Appellant, vs. The State of Florida, Appellee. An Appeal under Florida Rule of Appellate Procedure 9.141(b)(2) from the Circuit Court for Miami-Dade County, Jose L. Fernandez, Judge. Maurice Lindsey, in proper person. Ashley Moody, Attorney General, for appellee. Before LOGUE, SCALES and GORDO, JJ. PER CURIAM. Affirmed.
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

February 27, 2007 Clifford W. Taylor,

 Chief Justice 

132530 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee, 

Robert P. Young, Jr. 

Stephen J. Markman,

 Justices 

v SC: 132530 

 COA: 262415 

Saginaw CC: 02-021183-FC 

RONALD ALLEN JOHNSON,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the September 28, 2006 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court. 

p0220 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

February 27, 2007 

 Clerk
Exhibit 23.1





Consent of Independent Registered Public Accounting Firm





Hemispherx Biopharma, Inc.


Philadelphia, Pennsylvania





We consent to the incorporation by reference in Registration Statements (No.s 333-160499, 333-57134, 118903 and 333-155528) on Form S-8 and Registration Statements (No.s 333-136187, 333-117178,  333-119017, 333-108645, 333-111135, 333-113796, 333-130008, 333-159856 and 333-151696) on Form S-3 of Hemispherx Biopharma, Inc. and Subsidiaries of our reports dated March 28, 2011 relating to our audit of the consolidated financial statements and the financial statement schedule, and internal control over financial reporting, which appear in this Annual Report on Form 10-K of Hemispherx Biopharma, Inc. for the year ended December 31, 2010.





/s/ McGladrey & Pullen LLPMcGladrey & Pullen LLPBlue Bell, PennsylvaniaMarch 28, 2011
§ 607.1 Scope. ( a ) This part establishes establishment registration and product listing requirements for manufacturers of human blood and blood products.
( b ) This part establishes establishment registration and product listing requirements for manufacturers of products that meet the definition of a device under the Federal Food, Drug, and Cosmetic Act and that are licensed under section 351 of the Public Health Service Act, as well as licensed biological products used in the manufacture of a licensed device.
[81 FR 60221, Aug. 31, 2016]